You are in: eMedicine Specialties > Neurology > Movement and Neurodegenerative Diseases Writer's CrampArticle Last Updated: Nov 2, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Jonathan B Strober, MD, Director, Pediatric Muscular Dystrophy Association Clinic; Assistant Clinical Professor, Departments of Pediatrics and Neurology, Division of Child Neurology, University of California at San Francisco Jonathan B Strober is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, Child Neurology Society, and Society for Pediatric Research Editors: Stephen T Gancher, MD, Adjunct Associate Professor, Department of Neurology, Oregon Health Sciences University; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Nestor Galvez-Jimenez, MD, Program Director of Movement Disorders, Department of Neurology, Division of Medicine, Director of Neurology Residency Training Program, Cleveland Clinic Florida; Matthew J Baker, MD, Consulting Staff, Collier Neurologic Specialists, Naples Community Hospital; Nicholas Y Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants Author and Editor Disclosure Synonyms and related keywords: focal hand dystonia, graphospasm, musician's cramp, writer's cramp, focal dystonia, dystonic conditions, repetitive movements, spinal reciprocal inhibition INTRODUCTIONBackgroundWriter's cramp is a form of task-specific focal dystonia. Dystonia is an involuntary, sustained muscle contraction causing twisting movements and abnormal postures; focal dystonia means only one body part is affected. Writer's cramp is the most common dystonia occurring in the setting of repetitive movement disorders. A focal dystonia can sometimes be the first manifestation of a generalized dystonia. PathophysiologyNormally, an antagonist muscle relaxes when an agonist muscle is contracted. Patients with dystonia have simultaneous contraction of both groups of muscles. Spinal reciprocal inhibition, a process that inhibits the antagonist muscles when the agonist muscles are active, is reduced in patients with writer's cramp. This is most probably due to aberrant descending commands. Abnormalities in the basal ganglia lead to abnormalities of sensory processing and motor output. The normal increase in cerebral blood flow in the supplementary motor area is reduced in response to vibration and abnormal somatosensory evoked potentials. These provide evidence for the abnormal sensory processing in patients with dystonia. Increased motor cortex excitability along with decreased cortical inhibition causes abnormal motor output. FrequencyUnited StatesOne study estimated the prevalence to be 69 cases per 100,000 population; this is thought to be an underestimation because a high percentage of patients never seek medical assistance. InternationalAgain, because of the small percentage of affected patients seeking medical attention, accurate prevalence estimates are not available. SexPrevalence is slightly higher in men; the male-to-female ratio is 1.3:1. AgeTypically, patients present in the third to fifth decades, and women usually present earlier than men. CLINICALHistory
Physical
Causes
DIFFERENTIALSDopamine-Responsive Dystonia Multiple Sclerosis Parkinson Disease Wilson Disease
|
| Drug Name | Trihexyphenidyl (Artane) |
|---|---|
| Description | Substituted piperidine that inhibits parasympathetic system. Available as 2 mg tab or 2 mg/5 cc elixir. |
| Adult Dose | Start with 1 mg PO qd, then increase by 2 mg at intervals of 3-5 d up to 6-15 mg/d divided tid |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; glaucoma; peptic ulcer; pyloric or duodenal obstruction; stenosing prostatic hypertrophy or bladder neck obstructions; achalasia; toxic megacolon |
| Interactions | Amantadine may increase anticholinergic adverse effects, which disappear when dose reduced; when taken with haloperidol, may decrease haloperidol serum concentration, resulting in worsening of schizophrenic symptoms; may reduce pharmacologic/therapeutic actions of phenothiazines |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Dose adjustment may be required in geriatric patients; caution in patients with tachycardia, cardiac hypotension, prostatic hypertrophy, arrhythmias, hypertension, or any tendency toward urinary retention, liver or kidney disorders, or obstructive disease of GI or GU tract; if dry mouth severe and impairs swallowing or speaking, or if loss of appetite and weight occurs, reduce dosage or discontinue medication temporarily |
These agents help reduce the tremor.
| Drug Name | Propranolol (Inderal, Betachron E-R) |
|---|---|
| Description | Class II antiarrhythmic, nonselective, beta-adrenergic, receptor blocker with membrane-stabilizing activity that decreases automaticity of contractions. Available as 10 mg, 20 mg, 40 mg, and 80 mg tablets and 60 mg, 80 mg, 120 mg, and 160 mg long-acting tablets (Inderal LA) |
| Adult Dose | 40 mg PO bid initially; increase as tolerated; not to exceed 240-320 mg/d divided bid/tid |
| Pediatric Dose | 2-4 mg/kg PO divided bid; increase as tolerated; not to exceed 16 mg/kg/d |
| Contraindications | Documented hypersensitivity; uncompensated congestive heart failure; bradycardia; cardiogenic shock; AV conduction abnormalities |
| Interactions | Aluminum salts, barbiturates, NSAIDs, penicillins, calcium salts, cholestyramine, and rifampin may decrease effects; calcium channel blockers, cimetidine, loop diuretics, and MAOIs may increase toxicity; may increase toxicity of hydralazine, haloperidol, benzodiazepines, and phenothiazines |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May decrease signs of acute hypoglycemia and hyperthyroidism; abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm; withdraw drug slowly and monitor closely |
Neurotoxin complex blocks neuromuscular conduction by binding to receptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. When injected intramuscularly, it produces a localized chemical denervation muscle paralysis.
| Drug Name | Botulinum toxin type A (BOTOX®) |
|---|---|
| Description | Local intramuscular injections weaken overactive muscles, reducing dystonic symptoms. |
| Adult Dose | Injections usually given under EMG guidance and should be administered by physicians experienced in giving the injections |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Aminoglycosides or drugs that interfere with neuromuscular transmission may potentiate effects |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not exceed recommended dosages and frequencies of administration; presence of antibodies to botulinum toxin type A may reduce effects of therapy; not known if toxin excreted in breast milk |
Article Last Updated: Nov 2, 2006